Schwartz Investment Counsel Inc. raised its stake in shares of Chemed Co. (NYSE:CHE – Free Report) by 1.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 119,163 shares of the company’s stock after purchasing an additional 1,173 shares during the period. Chemed accounts for 2.3% of Schwartz Investment Counsel Inc.’s portfolio, making the stock its 12th largest position. Schwartz Investment Counsel Inc. owned about 0.79% of Chemed worth $63,133,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. UMB Bank n.a. grew its position in Chemed by 300.0% during the fourth quarter. UMB Bank n.a. now owns 52 shares of the company’s stock valued at $28,000 after acquiring an additional 39 shares during the period. Trust Co. of Vermont acquired a new stake in shares of Chemed in the fourth quarter worth $34,000. GAMMA Investing LLC increased its position in shares of Chemed by 60.5% in the third quarter. GAMMA Investing LLC now owns 138 shares of the company’s stock worth $83,000 after acquiring an additional 52 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Chemed by 2,314.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 338 shares of the company’s stock valued at $203,000 after acquiring an additional 324 shares during the period. Finally, KBC Group NV boosted its position in Chemed by 11.5% during the 3rd quarter. KBC Group NV now owns 378 shares of the company’s stock worth $227,000 after purchasing an additional 39 shares during the period. Hedge funds and other institutional investors own 95.85% of the company’s stock.
Chemed Price Performance
Shares of CHE stock opened at $553.94 on Wednesday. Chemed Co. has a 12 month low of $512.12 and a 12 month high of $654.62. The company’s fifty day moving average price is $542.65 and its two-hundred day moving average price is $564.84. The firm has a market capitalization of $8.34 billion, a P/E ratio of 27.99, a P/E/G ratio of 2.16 and a beta of 0.48.
Insider Buying and Selling at Chemed
Analyst Ratings Changes
Several research analysts have commented on the company. Royal Bank of Canada cut their price objective on Chemed from $697.00 to $633.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. StockNews.com upgraded Chemed from a “hold” rating to a “buy” rating in a research note on Saturday, November 30th.
Check Out Our Latest Stock Report on Chemed
Chemed Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Read More
- Five stocks we like better than Chemed
- 3 Best Fintech Stocks for a Portfolio Boost
- Citigroup Analysts Are Betting Big on These 3 Stocks—Should You?
- Earnings Per Share Calculator: How to Calculate EPS
- Johnson Controls: 5 Reasons to Own This Engineering Giant
- How to Use the MarketBeat Stock Screener
- Constellation Brands: A Fallen Star or a Hidden Value Play?
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.